Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Leqvio Market Growth Potential: How Will Market Size Change Through 2030?
The expansion observed during the historic period was fueled by a rising incidence of hyperlipidemia, progress in RNA interference approaches, a broader network of cardiovascular specialty facilities, heightened consciousness around controlling LDL cholesterol levels, and enhanced systems for administering injectable medications.
The expansion observed in the forecast period is driven by the growing uptake of innovative RNA therapeutics, a heightened focus on mitigating cardiovascular risks, the broader rollout of therapies with extended dosing intervals, rising financial commitments to cardiometabolic studies, and the escalating need for long-lasting lipid-reduction options. Key developments shaping this period encompass the rising use of siRNA-based strategies for lowering lipids, an increased appetite for durable cardiovascular interventions, a stronger orientation toward preventive cardiology approaches, the advancement of sophisticated RNA production techniques, and a greater priority placed on improving patient compliance with treatment regimens.
Download A Free Sample Report For Comprehensive Market Insights:
#Leqvio Market Growth Factors: Which Forces Are Supporting Market Expansion?
The rising number of older adults is anticipated to drive future demand for leqvio. This demographic is typically made up of individuals who are 65 years old or older. Improvements in healthcare and medical technologies have substantially increased life expectancy, which in turn has fueled the expansion of the elderly population. By lowering LDL cholesterol, leqvio simplifies medication management for seniors. Its prolonged effectiveness helps reduce the risk of cardiovascular events, thereby improving health outcomes among the geriatric group. For example, in January 2024, the Population Reference Bureau, a nonprofit organization based in Kenya, reported that the number of Americans aged 65 and above is forecast to grow from 58 million in 2022 to 82 million by 2050—a rise of 47%. During the same timeframe, this age bracket’s proportion of the total U.S. population is expected to increase from 17% to 23%. Consequently, the expanding geriatric population is fueling growth in the leqvio market.
Leqvio Market Segment Analysis And Revenue Opportunities
The leqvio market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors
2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia
3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions
4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers
Leqvio Market Industry Trends: What Changes Are Reshaping Demand?
Major players in the leqvio market are actively working on the development of advanced injectable prescription medicines, such as Label Expansion, which aims to improve therapeutic accessibility and facilitate early intervention. Label Expansion involves receiving regulatory permission from bodies like the FDA to broaden the use of an already approved drug for new indications, different patient populations, or alternative clinical settings beyond its initial authorization. For example, in July 2023, Novartis AG, a pharmaceutical firm based in Switzerland, secured approval from the US Food and Drug Administration (FDA) for a revised label for Leqvio (inclisiran), enabling its earlier application in patients with elevated LDL-C and heightened cardiovascular risk, alongside dietary modifications and statin therapy. Administered as two doses annually after an initial two-dose regimen, it achieves up to a 52% reduction in LDL-C and has demonstrated efficacy in patients who fail to meet their LDL-C objectives despite statin use. This label update is supported by strong safety and efficacy results from the VictORION clinical trial program.
Leqvio Market Leading Players Shaping Industry Direction
Major companies operating in the leqvio market are Novartis AG
Access The Complete Leqvio Market Report:
Leqvio Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model